MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â months

Additional file 1. Natural logarithm (ln) of fold change between baseline (T0) and long term anti-IgE treatment (T36) for each subject. Significant values (ln[Fold Change]>|0.6| are are reported in red or blue: positive (blue) and negative (red) values indicate increase and decrease at T36, respectively. Specifically, for ln(Fold Change) >0.6 (blue) increase at T36; on the contrary, if it is